Cetuximab KRAS Wild-Type Probability for Response

Assess KRAS/NRAS/BRAF mutation status impact on cetuximab and panitumumab response in metastatic colorectal cancer. RAS-mutated tumors do not benefit from EGFR antibodies.

Weight
Height
Clinical Guidance

BMI is a screening measure of body size, not a direct measure of body fat. The standard WHO categories are underweight (<18.5), normal (18.5–24.9), overweight (25–29.9), and obese (≥30).

BMI can overestimate body fat in athletes with high muscle mass and underestimate it in older adults with low muscle mass. Interpret it alongside waist circumference and clinical context rather than as a standalone diagnosis.

⚕ Clinical Disclaimer: These calculators are for educational and reference purposes only. Always verify results with qualified clinical judgment and current clinical guidelines. Do not use as a sole basis for medical decisions.
Advertisement

How It Works

Assess KRAS/NRAS/BRAF mutation status impact on cetuximab and panitumumab response in metastatic colorectal cancer. RAS-mutated tumors do not benefit from EGFR antibodies

Each component has a specific meaning:

  • EGFR antibodies — The egfr antibodies recorded for the scenario being assessed.

Note: Interpret the cetuximab kras wild-type result against the thresholds and context described above.

How to Use

Enter the EGFR antibodies for the scenario you are assessing. Assess KRAS/NRAS/BRAF mutation status impact on cetuximab and panitumumab response in metastatic colorectal cancer. RAS-mutated tumors do not benefit from EGFR antibodies. Use the cetuximab kras wild-type result to inform your calculation.

Frequently Asked Questions